EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐World Efficacy of Nab‐Paclitaxel Plus Capecitabine and a PD ‐1 Inhibitor in Metastatic or Locally Advanced Esophageal Cancer

Yun Wang, Wei-Jing Zhang, Yun-Xin Lu, Shi-Liang Liu, Zhuo-Yu Zhang, Si-Min Zhang, Tian-Wan Wang, Yu Zhong, Dong-Sheng Zhang

Cancer Medicine · 2026-03 · 15 (3)

DOI: 10.1002/cam4.71735 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 20.03.2026. Verfasst von Yun Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. Hauptthemen laut MEDLINE: Paclitaxel, Esophageal Neoplasms, Albumins, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tencent.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Over half of esophageal cancer (EC) cases occur in China, where paclitaxel and platinum agents have become the preferred chemotherapeutic regimen for EC patients. However, there is a clinical need for a non‐platinum‐based therapeutic option.

Methods

Cases were collected from Sun Yat‐sen University Cancer Center between January 2019 and November 2023. Patients with metastatic or locally advanced EC received 4–6 cycles of chemo‐immunotherapy, including nab‐paclitaxel, capecitabine, and a programmed death receptor 1 (PD‐1) inhibitor, with or without subsequent surgery, radiotherapy, or maintenance therapy. The objective response rate (ORR), disease control rate (DCR), progression‐free survival (PFS), pathological complete response (pCR), complete (R0) resection rate, and major pathologic response (MPR) were assessed.

Results

Among the 72 patients retrospectively analyzed, the median PFS was 24.7 months (95% confidence interval: 7.0–42.3 months). 75% of patients were regarded as responders, with an ORR of 66.7% in 42 patients with measurable lesions. The 6‐month, 1‐year, and 2‐year PFS rates (DCRs) were 100%, 96.2%, and 67.9%, respectively. In total, 9 patients underwent surgery, and 29 patients received radiotherapy following the regimen. The R0 resection rate was 77.8%, while both pCR and MPR were 66.7%. The most common adverse events were myelosuppression (27.8%) and liver dysfunction (25.0%).

Conclusion

Our study demonstrated that the combination of nab‐paclitaxel, capecitabine, and a PD‐1 inhibitor was an effective and tolerable strategy for EC patients and a promising first‐line or neoadjuvant treatment option.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelEsophageal NeoplasmsAlbuminsAntineoplastic Combined Chemotherapy ProtocolsCapecitabineImmune Checkpoint InhibitorsHumansFemaleMaleMiddle AgedAgedRetrospective StudiesPathologic Complete ResponseAdultTreatment Outcome

Stichwörter der Autor:innen

anti‐PD‐1 inhibitorcapecitabineesophageal cancernab‐paclitaxel

Substanzen

PaclitaxelAlbumins130-nm albumin-bound paclitaxelCapecitabineImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Department of Radiology, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Department of Radiation Oncology, Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Guangdong Provincial Key Laboratory of Food, Nutrition and Health, and Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou, China.
  • Integrated Traditional Chinese and Western Medicine Research Center, Sun Yat-sen University Cancer Center, Guangzhou, China.

Förderung

  • Tencent

Zitieren

APA

Wang, Y., Zhang, W. J., Lu, Y. X., Liu, S. L., Zhang, Z. Y., Zhang, S. M., Wang, T. W., Zhong, Y., & Zhang, D. S. (2026). Real‐World Efficacy of Nab‐Paclitaxel Plus Capecitabine and a PD ‐1 Inhibitor in Metastatic or Locally Advanced Esophageal Cancer. Cancer Medicine, 15(3). https://doi.org/10.1002/cam4.71735

Vancouver

Wang Y, Zhang WJ, Lu YX, Liu SL, Zhang ZY, Zhang SM, et al. Real‐World Efficacy of Nab‐Paclitaxel Plus Capecitabine and a PD ‐1 Inhibitor in Metastatic or Locally Advanced Esophageal Cancer. Cancer Medicine. 2026;15(3). doi:10.1002/cam4.71735

BibTeX
@article{Wang2026,
  author = {Wang, Yun and Zhang, Wei-Jing and Lu, Yun-Xin and Liu, Shi-Liang and Zhang, Zhuo-Yu and Zhang, Si-Min and Wang, Tian-Wan and Zhong, Yu and Zhang, Dong-Sheng},
  title = {Real‐World Efficacy of Nab‐Paclitaxel Plus Capecitabine and a PD ‐1 Inhibitor in Metastatic or Locally Advanced Esophageal Cancer},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {3},
  doi = {10.1002/cam4.71735}
}
Kostenlos starten →